Episode Details
Back to Episodes
TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions
Description
In this episode, Dr Matthew Gubens and Dr Helena Yu discuss the evolving role of TROP2-directed therapies in non-small-cell lung cancer, with a focus on how antibody–drug conjugates (ADCs) fit into current treatment strategies, including
- The mechanism of action and clinical trial outcomes of TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan
- Use of these therapies in EGFR-mutant disease and how they fit into a changing treatment landscape
- Practical advice on associated adverse events and additional considerations,
- A look at future directions on the horizon, such as first-line studies and predictive biomarkers
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Matthew Gubens, MD, MS, FASCO
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California
Helena Yu, MD
Professor of Medicine
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Link to full program:
https://bit.ly/41vAnfH
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.